

WAY

19

# 340B Drug Discounts and Quality 503A, 503B Compounding Make Avella an Industry Leader

By partnering with Avella Specialty Pharmacy, hospitals have access to one partner for all of their specialty drug and 503A and 503B outsourcing needs. We've become a recognized industry leader by providing premier service, rapid turnarounds, and rigorous quality assurance.

**President & CEO:** Rebecca Shanahan

Founded: 1996

Employees: 600

Toll-Free Phone: (877) 546-5779

Fax: (877) 546-5780

Address: 24416 N 19th Avenue, Phoenix, AZ 85085

Website: [www.avella.com](http://www.avella.com)



## Company Background

Avella is a leading, omni-channel provider of innovative compounding services and breakthrough specialty drugs. In addition to our community pharmacy locations in multiple states, Avella has a national distribution facility and two cGMP compliant clean rooms in TX and AZ. In fact, we were one of the first organizations to become a registered 503B facility through the FDA. In 2017, Avella purchased Advanced Pharma, securing our position as an industry leader in providing both 503A and 503B compounded therapies. We also work with hospitals as an extension of their 340B drug discount programs, helping these organizations secure valuable discounts that allow them to better support underserved populations. With more than 20 years of experience in this space, we have the clinical expertise and industry understanding needed to be a true partner to hospitals and health systems of all sizes.

## Product Overview

Just like the organizations we serve, Avella is laser-focused on improving quality, health outcomes, and patient safety. All of our products are developed with these priorities in mind.

■ **SourceB 503B Products:** Avella's SourceB sterile preparations include IV injectable drugs such as PCAs, epidurals, admixtures, nerve blocks, and OR syringes used within the acute care setting. These include many difficult-to-source products. All of these therapies are produced in one of our two cGMP-compliant clean rooms. Together, these facilities encompass more than 80,000 square feet. Avella leverages this operational redundancy to ensure we can always deliver on-time and on-demand for our customers.

Avella's FDA-registered 503B outsourcing facilities maintain compliance with all cGMP requirements for safety and quality. This mentality is embedded within all of our standard operating procedures.

- Both the AZ and TX facilities exceed USP Chapter <797> and cGMP standards.
- Avella only procures sterile drugs and reservoirs from the most reputable, FDA-registered manufacturers.
- We employ state-of-the-art automation resources to improve production efficiency and maintain unsurpassed quality.

- We perform potency, sterility, and endotoxin testing on all end-products.
- Our quality assurance team oversees all of the processes related to development, quality, and distribution of these products.
- We go above-and-beyond in the area of patient safety.

Avella also extends our commitment to quality beyond these clean rooms. Our premier service, intuitive online ordering, rapid turnarounds, and dynamic product portfolio are all designed to streamline and ease the workload of your pharmacy staff, meeting even the most challenging outsourcing demands.

■ **503A Patient-Specific Compounding:** In addition, Avella offers patient-specific, specialty infusion products for 503A which include the latest breakthrough oncology drugs. These patient-specific, unit-dosed chemotherapy drugs are used in IV or other specialized administration. They are formulated by Avella's highly trained pharmacy staff, clinical experts with extensive experience producing high-risk oncology compounds. All of our 503A products are produced in a USP 800-compliant, 5,000 square-foot facility.

■ **340B Drug Discount Program Partnerships:** Finally, Avella is a designated 340B contract pharmacy, collaborating with qualifying organizations across the country to provide valuable drug discounts. The government's 340B program promotes access to affordable medications for vulnerable or underserved patient populations while helping stretch federal resources. The program meets this goal by mandating that drug manufacturers must provide outpatient drugs at discounted prices to certain qualifying hospitals and healthcare organizations, often provided through designated 340B pharmacies.

For hospitals that are qualified entities, this potential savings can be significant. According to the American Hospital Association, 340B already saves hospitals \$1.6 - 3.8 billion per year.

## Products

■ **Sterile IV Injectable Products Include:** OR Syringes, PCA, Epidural, Nerve Blocks, Admixtures, and Elastomeric Pumps.

We offer specialty drugs across a variety of therapeutic areas including: oncology, infectious diseases (HIV, Hepatitis C), addition management, pain management, urology, cardiovascular disease, rheumatology, MS, gastroenterology, RSV, asthma, dermatology, IG therapy, and transplant.

## Contact Information

To learn more about this program or Avella's 503A and 503B compounding capabilities, please visit [www.avella.com/hospitals](http://www.avella.com/hospitals).